Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Cyclophosphamide
/ therapeutic use
Disease Progression
Doxorubicin
/ therapeutic use
Female
Humans
Lenalidomide
/ therapeutic use
Lymphoma, Follicular
/ pathology
Lymphoma, Large B-Cell, Diffuse
/ drug therapy
Male
Middle Aged
Prednisone
/ therapeutic use
Progression-Free Survival
Rituximab
/ therapeutic use
Treatment Outcome
Vincristine
/ therapeutic use
Young Adult
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
25 09 2021
25 09 2021
Historique:
received:
10
05
2021
accepted:
29
07
2021
revised:
16
07
2021
entrez:
26
9
2021
pubmed:
27
9
2021
medline:
5
2
2022
Statut:
epublish
Résumé
Diffuse large B-cell lymphoma (DLBCL), either concurrent with or transformed from follicular lymphoma (FL) is often excluded from clinical trials. Lenalidomide has response rates of 45% in relapsed transformed DLBCL. Herein we present an analysis of MC078E, a phase II clinical trial testing lenalidomide plus R-CHOP (R2CHOP) for patients with untreated transformed/concurrent DLBCL (NCT00670358). Adult patients with transformed or concurrent DLBCL were included. Patients received six cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) with lenalidomide 25 mg days 1-10 of each cycle. The primary outcome was progression-free survival (PFS) at 24 months. Secondary outcomes were response rates, event-free survival (EFS), and overall survival (OS). Thirty-nine patients were accrued from August 5, 2013 to July 28, 2020 and 33 were eligible by central pathology review. The median age was 64 (24-80) years, 18 (54%) were male, 25 (76%) were concurrent and 8 (24%) were transformed DLBCL. The PFS, EFS, and OS rates at 24 months were 84.4% (CI
Identifiants
pubmed: 34564694
doi: 10.1038/s41408-021-00542-z
pii: 10.1038/s41408-021-00542-z
pmc: PMC8464592
doi:
Substances chimiques
R-CHOP protocol
0
Rituximab
4F4X42SYQ6
Vincristine
5J49Q6B70F
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Lenalidomide
F0P408N6V4
Prednisone
VB0R961HZT
Types de publication
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
160Informations de copyright
© 2021. The Author(s).
Références
Cancer. 2011 Nov 15;117(22):5058-66
pubmed: 21495023
Cancer Immunol Immunother. 2008 Dec;57(12):1849-59
pubmed: 18392823
J Clin Oncol. 1995 Jul;13(7):1726-33
pubmed: 7602362
Cancer Cell. 2012 Jun 12;21(6):723-37
pubmed: 22698399
Ann Oncol. 2015 Feb;26(2):393-9
pubmed: 25411416
N Engl J Med. 2018 Sep 6;379(10):934-947
pubmed: 30184451
J Clin Oncol. 2004 Apr 15;22(8):1454-9
pubmed: 15024027
Science. 2014 Jan 17;343(6168):301-5
pubmed: 24292625
Clin Cancer Res. 2008 Jul 15;14(14):4650-7
pubmed: 18628480
Lancet Oncol. 2020 Jul;21(7):978-988
pubmed: 32511983
Blood. 2019 Aug 29;134(9):761-764
pubmed: 31300404
J Clin Oncol. 2019 May 10;37(14):1188-1199
pubmed: 30897038
J Clin Oncol. 2021 Apr 20;39(12):1329-1338
pubmed: 33555941
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):306-311
pubmed: 33275671
Blood. 2019 Oct 17;134(16):1289-1297
pubmed: 31350266
Ann Oncol. 2011 Jul;22(7):1622-1627
pubmed: 21228334
J Clin Oncol. 2008 Oct 20;26(30):4952-7
pubmed: 18606983
J Clin Oncol. 2021 Apr 20;39(12):1314-1316
pubmed: 33621123
Leukemia. 2013 Sep;27(9):1902-9
pubmed: 23545991
Br J Haematol. 2013 Nov;163(4):487-95
pubmed: 24111533
Hematol Oncol Clin North Am. 2016 Dec;30(6):1163-1177
pubmed: 27888873
J Clin Oncol. 2008 Nov 10;26(32):5165-9
pubmed: 18838711
Blood. 2015 Apr 16;125(16):2471-6
pubmed: 25736312
Blood. 2015 Aug 13;126(7):851-7
pubmed: 26105149
J Clin Oncol. 2021 Apr 20;39(12):1317-1328
pubmed: 33621109
J Clin Oncol. 2007 Feb 10;25(5):579-86
pubmed: 17242396
Hematol Oncol. 2019 Apr;37(2):143-150
pubmed: 30840776
Br J Haematol. 2017 Sep;178(5):699-708
pubmed: 28782811
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
J Clin Oncol. 2013 Sep 10;31(26):3272-8
pubmed: 23897955
Clin Cancer Res. 2019 Jan 1;25(1):90-98
pubmed: 30201761
J Clin Oncol. 2015 Jan 20;33(3):251-7
pubmed: 25135992
J Clin Oncol. 1997 Aug;15(8):2945-53
pubmed: 9256139